Bill Text: AZ SB1401 | 2012 | Fiftieth Legislature 2nd Regular | Introduced
Bill Title: Prescription drugs; maximum expense limitation
Spectrum: Partisan Bill (Republican 3-0)
Status: (Introduced - Dead) 2012-02-14 - Referred to Senate RULES Committee [SB1401 Detail]
Download: Arizona-2012-SB1401-Introduced.html
|
REFERENCE TITLE: prescription drugs; maximum expense limitation |
|
State of Arizona Senate Fiftieth Legislature Second Regular Session 2012
|
|
SB 1401 |
|
|
|
Introduced by Senators Murphy: Barto, McComish
|
AN ACT
Amending section 20‑841.05, Arizona Revised Statutes; amending title 20, chapter 4, article 3, Arizona Revised Statutes, by adding section 20-848; amending section 20‑1057.02, Arizona Revised Statutes; amending title 20, chapter 4, article 9, Arizona Revised Statutes, by adding section 20-1057.13; amending title 20, chapter 6, article 4, Arizona Revised Statutes, by adding sections 20‑1342.07 and 20‑1342.08; Amending title 20, chapter 6, article 5, Arizona Revised Statutes, by adding sections 20‑1402.05, 20‑1402.06, 20‑1404.05 and 20‑1404.06; relating to health insurance.
(TEXT OF BILL BEGINS ON NEXT PAGE)
Be it enacted by the Legislature of the State of Arizona:
Section 1. Section 20-841.05, Arizona Revised Statutes, is amended to read:
20-841.05. Prescription drug formulary; definitions
A. A corporation with a prescription drug benefit that uses a drug formulary as a component of the subscription contract shall provide to its subscribers notice in the contract and any disclosure form regarding the applicable drug formulary. The corporation shall write the notice so that the language and format are easy to understand. The notice shall include an explanation of what a drug formulary is, how the corporation determines which prescription drugs are included or excluded and how often the corporation reviews the contents of the drug formulary.
B. A corporation described in subsection A of this section shall:
1. Develop and maintain a process by which health care professionals may request authorization for a medically necessary formulary or nonformulary prescription drug during nonbusiness hours. If the corporation does not maintain that process, the corporation shall reimburse a subscriber for the subscriber's out‑of‑pocket expense minus any deductible or copayment for a prescription drug that was purchased by the subscriber without preauthorization but that was later approved by the corporation.
2. Develop and maintain a process by which health care professionals may request authorization for medically necessary nonformulary prescription drugs. The corporation shall approve an alternative prescription drug when either of the following conditions is met:
(a) The equivalent prescription drug on the formulary has been ineffective in the treatment of the subscriber's disease or condition.
(b) The equivalent prescription drug on the formulary has caused an adverse or harmful reaction in the subscriber.
C. If the subscriber's pharmacy benefit plan does not require authorization, subsection B, paragraph 2 of this section does not apply.
D. If the subscriber's treating health care professional makes a determination that the subscriber meets any of the conditions described in subsection B of this section, any denial to cover the nonformulary prescription drug by the corporation shall be made in writing by a licensed pharmacist or medical director. The written denial shall contain an explanation of the denial, including the medical or pharmacological reasons why the authorization was denied, and the licensed pharmacist or medical director who made the denial shall sign it. The corporation shall send a copy of the written denial to the subscriber's treating health care professional who requested the authorization. The corporation shall maintain copies of all written denials and shall make the copies available to the department for inspection during regular business hours.
E. Any subscription contract that is issued, amended or renewed by a corporation and that includes prescription drug benefits shall not limit or exclude coverage for at least sixty days after the corporation's notice or the pharmacy's notice pursuant to subsection F of this section to the subscriber, whichever occurs first, for a prescription drug for a subscriber to refill a previously prescribed drug if the prescription drug was previously approved for coverage under the drug formulary or pharmacy benefit plan for the subscriber's medical condition and the health care professional continues to prescribe the prescription drug for the same medical condition. The limitation or exclusion prohibited by this subsection applies if the prescription drug is appropriately prescribed and is considered safe and effective for treating the subscriber's medical condition. This subsection does not prohibit the health care professional from prescribing another prescription drug that is covered by the drug formulary and that is medically appropriate for the subscriber, including generic drug substitutions.
F. A corporation shall provide written notice of the removal of any prescription drug from the corporation's drug formulary to each pharmacy vendor with which the corporation has a contract. On notice from the corporation, the contracted pharmacy vendor at the point of dispensing a prescription drug that has been removed from the drug formulary shall notify the subscriber by means of a verbal consultation or other direct communication with a subscriber that the subscriber may be required to consult with a health care professional to obtain a new prescription for a replacement drug after the sixty day period prescribed in subsection E of this section. The notice prescribed in this subsection is not required if the pharmacy vendor is a pharmacy that is owned by the corporation or a corporate affiliate of that corporation.
G. A corporation with a prescription drug benefit that uses a multitiered drug formulary as a component of a subscription contract shall not reclassify biologics or a plasma‑derived prescription drug to a higher cost tier of the formulary during the term of the subscription contract. If a corporation plans to reclassify biologics or a plasma‑derived prescription drug to a lower or higher cost tier of the formulary in a subsequent term of the subscription contract, the corporation shall give the subscriber sixty days' notice regarding the impending change and publish the impending change on the corporation's website in a manner that is accessible to and searchable by subscribers and providers.
H. If a subscription contract for hospital and medical coverage includes a prescription drug benefit that requires deductibles, copayments, coinsurance or other out‑of‑pocket expenses to be paid by a subscriber, the cumulative costs paid by a subscriber for deductibles, copayments, coinsurance or other out‑of‑pocket expenses for prescription drugs during the term of the subscription contract shall be applied toward any annual out‑of‑pocket maximum amount contained in the subscription contract.
G. I. This section does not:
1. Prohibit a corporation from applying deductibles, coinsurance or other cost containment or quality assurance measures.
2. Apply to a corporation that provides a multitiered benefit plan that allows access to prescription drugs without authorization by the corporation.
3. Apply to any corporation that holds a certificate of authority to operate either as a dental service corporation or an optometric service corporation.
H. J. For the purposes of this section:
1. "Health care Professional" means a person who has an active nonrestricted license pursuant to title 32 and who is authorized to write drug prescriptions to treat medical conditions.
2. "Prescription drug" means any prescription medication as defined in section 32‑1901 that is prescribed by a health care professional to a subscriber to treat the subscriber's condition.
Sec. 2. Title 20, chapter 4, article 3, Arizona Revised Statutes, is amended by adding section 20-848, to read:
20-848. Out-of-pocket expenses; limitation
Notwithstanding any other law, the maximum amount of annual out‑of‑pocket expenses that may be charged by a corporation to a subscriber during the term of a subscription contract may not exceed _________________.
Sec. 3. Section 20-1057.02, Arizona Revised Statutes, is amended to read:
20-1057.02. Prescription drug formulary; definitions
A. A health care services organization with a prescription drug benefit that uses a drug formulary as a component of the evidence of coverage shall provide to its enrollees notice in the evidence of coverage and the disclosure form prescribed in section 20‑1076 regarding the applicable drug formulary. The health care services organization shall write the notice so that the language and format are easy to understand. The notice shall include an explanation of what a drug formulary is, how the health care services organization determines which prescription drugs are included or excluded and how often the health care services organization reviews the contents of the drug formulary.
B. A health care services organization described in subsection A of this section shall:
1. Develop and maintain a process by which health care professionals may request authorization for a medically necessary formulary or nonformulary prescription drug during nonbusiness hours. If the health care services organization does not maintain that process, the health care services organization shall reimburse an enrollee for the enrollee's out‑of‑pocket expense minus any deductible or copayment for a prescription drug that was purchased by the enrollee without preauthorization but that was later approved by the health care services organization.
2. Develop and maintain a process by which health care professionals may request authorization for medically necessary nonformulary prescription drugs. The health care services organization shall approve an alternative prescription drug when either of the following conditions is met:
(a) The equivalent prescription drug on the formulary has been ineffective in the treatment of the enrollee's disease or condition.
(b) The equivalent prescription drug on the formulary has caused an adverse or harmful reaction in the enrollee.
C. If the health care services organization's pharmacy benefit plan does not require authorization, subsection B, paragraph 2 of this section does not apply.
D. If the enrollee's treating health care professional makes a determination that the enrollee meets any of the conditions described in subsection B of this section, any denial to cover the nonformulary prescription drug by the health care services organization shall be made in writing by a licensed pharmacist or medical director. The written denial shall contain an explanation of the denial, including the medical or pharmacological reasons why the authorization was denied, and the licensed pharmacist or medical director who made the denial shall sign it. The health care services organization shall send a copy of the written denial to the enrollee's treating health care professional who requested the authorization. The health care services organization shall maintain copies of all written denials and shall make the copies available to the department for inspection during regular business hours.
E. Any evidence of coverage that is issued, amended or renewed by a health care services organization and that includes prescription drug benefits shall not limit or exclude coverage for at least sixty days after the health care services organization's notice or the pharmacy's notice pursuant to subsection F of this section to the enrollee, whichever occurs first, for a prescription drug for an enrollee to refill a previously prescribed drug if the prescription drug was previously approved for coverage under the drug formulary or pharmacy benefit plan for the enrollee's medical condition and the health care professional continues to prescribe the prescription drug for the same medical condition. The limitation or exclusion prohibited by this subsection applies if the prescription drug is appropriately prescribed and is considered safe and effective for treating the enrollee's medical condition. This subsection does not prohibit the health care professional from prescribing another prescription drug that is covered by the drug formulary and that is medically appropriate for the enrollee, including generic drug substitutions.
F. A health care services organization shall provide written notice of the removal of any prescription drug from the health care services organization's drug formulary to each pharmacy vendor with which the health care services organization has a contract. On notice from the health care services organization, the contracted pharmacy vendor at the point of dispensing a prescription drug that has been removed from the drug formulary shall notify the enrollee by means of a verbal consultation or other direct communication with an enrollee that the enrollee may be required to consult with a health care professional to obtain a new prescription for a replacement drug after the sixty day period prescribed in subsection E of this section. The notice prescribed in this subsection is not required if the pharmacy vendor is a pharmacy that is owned by a health care services organization or a corporate affiliate of that health care services organization.
G. A health care services organization with a prescription drug benefit that uses a multitiered drug formulary as a component of an evidence of coverage shall not reclassify biologics or a plasma‑derived prescription drug to a higher cost tier of the formulary during the term of the evidence of coverage. If a health care services organization plans to reclassify biologics or a plasma‑derived prescription drug to a lower or higher cost tier of the formulary in a subsequent term of the evidence of coverage, the health care services organization shall give the enrollee sixty days' notice regarding the impending change and publish the impending change on the health care services organization's website in a manner that is accessible to and searchable by enrollees and providers.
H. If an evidence of coverage for hospital and medical coverage includes a prescription drug benefit that requires deductibles, copayments, coinsurance or other out‑of‑pocket expenses to be paid by an enrollee, the cumulative costs paid by an enrollee for deductibles, copayments, coinsurance or other out‑of‑pocket expenses for prescription drugs during the term of the evidence of coverage shall be applied toward any annual out‑of‑pocket maximum amount contained in the evidence of coverage.
G. I. This section does not:
1. Prohibit a health care services organization from applying deductibles, coinsurance or other cost containment or quality assurance measures.
2. Apply to a health care services organization that provides a multitiered benefit plan that allows access to prescription drugs without authorization by the health care services organization.
H. J. For the purposes of this section:
1. "Health care professional" means a person who has an active nonrestricted license pursuant to title 32 and who is authorized to write drug prescriptions to treat medical conditions.
2. "Prescription drug" means any prescription medication as defined in section 32‑1901 that is prescribed by a health care professional to an enrollee to treat the enrollee's condition.
Sec. 4. Title 20, chapter 4, article 9, Arizona Revised Statutes, is amended by adding section 20-1057.13, to read:
20-1057.13. Out-of-pocket expenses; limitation
Notwithstanding any other law, the maximum amount of annual out‑of‑pocket expenses that may be charged by a health care services organization to an enrollee during the term of an evidence of coverage may not exceed __________________________.
Sec. 5. Title 20, chapter 6, article 4, Arizona Revised Statutes, is amended by adding sections 20-1342.07 and 20‑1342.08, to read:
20-1342.07. Prescription medications; formularies; notice; out‑of‑pocket expenses
A. A disability insurer with a prescription drug benefit that uses a multitiered drug formulary as a component of a disability insurance policy shall not reclassify biologics or a plasma‑derived prescription drug to a higher cost tier of the formulary during the term of the policy. If a disability insurer plans to reclassify biologics or a plasma‑derived prescription drug to a lower or higher cost tier of the formulary in a subsequent term of the disability insurance policy, the disability insurer shall give the insured sixty days' notice regarding the impending change and publish the impending change on the disability insurer's website in a manner that is accessible to and searchable by insureds and providers.
B. If a disability insurance policy for hospital and medical coverage includes a prescription drug benefit that requires deductibles, copayments, coinsurance or other out‑of‑pocket expenses to be paid by an insured, the cumulative costs paid by an insured for deductibles, copayments, coinsurance or other out‑of‑pocket expenses for prescription drugs during the term of the disability insurance policy shall be applied toward any annual out‑of‑pocket maximum amount contained in the disability insurance policy.
20-1342.08. Out‑of‑pocket expenses; limitation
Notwithstanding any other law, the maximum amount of annual out‑of‑pocket expenses that may be charged by a disability insurer to an insured during the term of a disability insurance policy may not exceed ______________________.
Sec. 6. Title 20, chapter 6, article 5, Arizona Revised Statutes, is amended by adding sections 20-1402.05, 20‑1402.06, 20‑1404.05 and 20‑1404.06, to read:
20-1402.05. Prescription medications; formularies; notice; out‑of‑pocket expenses
A. A group disability insurer with a prescription drug benefit that uses a multitiered drug formulary as a component of a group disability policy shall not reclassify biologics or a plasma‑derived prescription drug to a higher cost tier of the formulary during the term of the policy. If a group disability insurer plans to reclassify biologics or a plasma‑derived prescription drug to a lower or higher cost tier of the formulary in a subsequent term of the group disability policy, the disability insurer shall give the insured sixty days' notice regarding the impending change and publish the impending change on the disability insurer's website in a manner that is accessible to and searchable by insureds and providers.
B. If a group disability policy for hospital and medical coverage includes a prescription drug benefit that requires deductibles, copayments, coinsurance or other out‑of‑pocket expenses to be paid by an insured, the cumulative costs paid by an insured for deductibles, copayments, coinsurance or other out‑of‑pocket expenses for prescription drugs during the term of the group disability policy shall be applied toward any annual out‑of‑pocket maximum amount contained in the group disability policy. END_STATUTE
20-1402.06. Out‑of‑pocket expenses; limitation
Notwithstanding any other law, the maximum amount of annual out‑of‑pocket expenses that may be charged by a group disability insurer to an insured during the term of a group disability policy may not exceed ______________________.
20-1404.05. Prescription medications; formularies; notice; out‑of‑pocket expenses
A. A blanket disability insurer with a prescription drug benefit that uses a multitiered drug formulary as a component of a blanket disability policy shall not reclassify biologics or a plasma‑derived prescription drug to a higher cost tier of the formulary during the term of the policy. If a blanket disability insurer plans to reclassify biologics or a plasma‑derived prescription drug to a lower or higher cost tier of the formulary in a subsequent term of the blanket disability policy, the blanket disability insurer shall give the insured sixty days' notice regarding the impending change and publish the impending change on the blanket disability insurer's website in a manner that is accessible to and searchable by insureds and providers.
B. If a blanket disability policy for hospital and medical coverage includes a prescription drug benefit that requires deductibles, copayments, coinsurance or other out‑of‑pocket expenses to be paid by an insured, the cumulative costs paid by an insured for deductibles, copayments, coinsurance or other out‑of‑pocket expenses for prescription drugs during the term of the blanket disability policy shall be applied toward any annual out‑of‑pocket maximum amount contained in the blanket disability policy.
20-1404.06. Out‑of‑pocket expenses; limitation
Notwithstanding any other law, the maximum amount of annual out‑of‑pocket expenses that may be charged by a blanket disability insurer to an insured during the term of a blanket disability policy may not exceed ________________________.
